Bharat Biotech Announces Clinical Trials of COVID-19 Vaccine

Hyderabad-based Bharat Biotech has announced the clinical trials of India's first indigenous COVID-19 vaccine Covaxin began across the country on July 15.

The Phase-I clinical trials have began for Hyderabad-based Bharat Biotech's COVID-19 vaccine Covaxin. The clinical trials were started across the country on July 15.

"This is a randomised, double-blind, placebo-controlled clinical trial on 375 volunteers in India," the company said in a brief statement.

COVID-19 Vaccine: Where Do We Stand Now?
COVID-19: The biggest challenge with the pandemic lies in not only developing a successful vaccine but also producing it in quantities necessary to provide immunity to all citizens. Competition is already emerging over who will have access once a vaccine is ready.

‘The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine was developed and manufactured in Bharat Biotech's BSL-3A (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad.’

The leading vaccine maker had announced on June 29 that it successfully developed Covaxin in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).

The Drug Controller General of India - Central Drugs Standard Control Organisation (CDSCO), Ministry of Health & Family Welfare granted permission to initiate Phase-I and II human clinical trials after the company submitted results generated from pre-clinical studies, demonstrating safety and immune response. The Nizam's Institute of Medical Science (NIMS), Hyderabad is one of the 12 centres selected by the ICMR for the clinical trials.

The subject enrolment for Phase-I clinical trials at the NIMS began on July 7. There was no clarity on the number of subjects selected at this centre.

Moderna's COVID-19 Vaccine Safe, Generates Immune Response
New vaccine manufactured by Moderna, mRNA-1273 is designed to induce neutralizing antibodies directed at a portion of the coronavirus spike protein, which the virus uses to bind to and enter human cells.

The officials had earlier said that for two days after administering the vaccine, the subjects would be monitored in the ICCU at the NIMS by a team of doctors, after which they would be sent home and monitored through video conference or phone.

The Phase-I clinical trial would go on for 28 days, after which the ICMR and Drug Controller General of India would accord permission for Phase-II, which will include more subjects.

Moderna COVID-19 Vaccine Shows Promising Results
US-based pharmaceutical major Moderna's experimental vaccine, mRNA-1273, designed to protect against COVID-19 virus, was generally well tolerated and prompted neutralising antibody response.

Phase-1 would have around 375 subjects across the country and Phase-II, 875.

In a letter to the selected centres early this month, ICMR Director General Balram Bhargava asked them to fast-track all approvals related to initiation of the clinical trial.

Russia 1st Nation to Successfully Finish Human Trials for Potential COVID-19 Vaccine
In a major positive development in the global fight against novel coronavirus, Russia has become the first nation to have completed the world's first-ever clinical trial of a potential COVID-19 vaccine candidate on humans.

"It is envisaged to launch the vaccine for public health use latest by 15th August 2020 after completion of all clinical trials. BBIL is working expeditiously to meet the target, however the final outcome will depend on the cooperation of all clinical trial sites involved in this project," reads the letter dated July 2.

While experts raised doubts on the August 15 target, the ICMR defended it, saying its process is in accordance with the globally accepted norms to fast-track vaccine development for diseases of pandemic potential.

The research body said Bhargava's letter was intended to cut red-tape, without bypassing any necessary process, and speed up recruitment of participants for human trials so that these phases can be completed at the earliest.

Bharat Biotech had refused to comment on the ICMR's August 15 deadline.

Source-IANS